Drug Discovery and Development

Why has it taken so long, historically, to bring a new drug to market? In a word: complexity. At one end of the spectrum, there is the complexity of disease, genetic variability, the presence of environmental variables that cause patients to respond differently to the same treatment. The thread extends into clinical development, where the…

Negative biosensors have often been unusable because, as the sensors lose signal when activity is detected, regions of high enzyme activity can look identical to regions with no activity. Researchers at the University of Illinois Chicago have solved this problem with a new cell imaging method that allows scientists to see previously hidden enzyme activities by flipping the optical readout of…

The U.S. entered August with more measles cases so far this year than it recorded during all of 2025. With kindergarten MMR coverage down to 92.5% from 95.2% before the pandemic, and Stanford modeling published in JAMA projecting measles could become endemic again within roughly two decades at current rates, President Donald Trump issued a…

As evidence mounts that some hormone receptor-positive, HER2-negative breast cancer patients are being overtreated with chemotherapy, researchers are working to identify which patients can safely avoid it, and to expand the treatment options available to those who can. Atossa Therapeutics thinks endoxifen, the active metabolite behind tamoxifen, could be an important addition to that toolkit.  …